A phase 2 study, multicenter, open label trial of R1415 (erlotinib hydrochloride) in patients with advanced, metastatic or recurrent non-small cell lung cancer.(JO16565)
Latest Information Update: 23 Apr 2022
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 17 Jun 2016 New trial record